Table 1 Patient’s characteristics
n | 34 |
|---|---|
Age | 57.2y (37–74) |
Location of primary tumor | |
Frontal Parietal Temporal Occipital Base of skull | 18 10 4 1 1 |
Type of resection 1st surgery (Simpson) | |
1–2 3–4 5 | 12 20 2 |
Reason for WHO 3 | |
Histopathology criteria CDKN2A deletion Mitotic > 20 | 16 10 24 |
1p loss (more than 50%) | 55.8% |
Karnofsky status | 80 (70–100) |
Total dose deliver 1st | 60 Gy (54–60) |
2nd surgery (yes) | 25 (73%) |
Total dose deliver 2nd | 35 Gy (25-40.05) |
Number of fractions | 10 (5–15) |
BED 2nd RT (α/β = 10) Median, range | 48.8 (31.2–56) |
Bed > 50 Gy | 16 (47%) |
concomitant Bevacizumab (yes)% | 12 (35.3%) |
PTV 2ND RT | 35 cc (11.5-212.4 cc) |
Median follow up (range) | 13 (5–28 months) |